In contrast, flow cytometry-based DDR is not suitable to confirm FA, DC, defects in BER, NER, MMR pathways, and the SWI/SNF complex, or other cancer susceptibility syndromes (Table 3). The gene discussed is SMARCA1; the disease is cancer.